Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,284,652 | $1,287,692 | $613,073 | $2,958,669 |
| - Cash | $83,433 | $48,875 | $94,172 | $231,900 |
| + Debt | $79,369 | $97,607 | $8,088 | $8,739 |
| Enterprise Value | $1,280,588 | $1,336,424 | $526,989 | $2,735,508 |
| Revenue | $235,133 | $175,513 | $134,030 | $45,605 |
| % Growth | 34% | 31% | 193.9% | – |
| Gross Profit | $206,885 | $161,365 | $128,366 | $44,514 |
| % Margin | 88% | 91.9% | 95.8% | 97.6% |
| EBITDA | $31,728 | -$63,047 | -$103,646 | -$177,445 |
| % Margin | 13.5% | -35.9% | -77.3% | -389.1% |
| Net Income | $5,752 | -$78,020 | -$108,180 | -$180,966 |
| % Margin | 2.4% | -44.5% | -80.7% | -396.8% |
| EPS Diluted | 0.039 | -0.54 | -0.76 | -1.4 |
| % Growth | 107.3% | 28.9% | 45.7% | – |
| Operating Cash Flow | $44,388 | -$33,461 | -$79,529 | -$157,692 |
| Capital Expenditures | -$281 | -$718 | -$292 | -$1,501 |
| Free Cash Flow | $44,107 | -$34,179 | -$79,821 | -$159,193 |